Robert Radinsky
Impact in
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
- Oncology 58
- Cancer Cells and Metastasis 16
- Cancer-related Molecular Pathways 14
- Colorectal Cancer Treatments and Studies 11
-
- Cancer, Hypoxia, and Metabolism 30
- Co-authors
- Isaiah J. Fidler (15 shared papers)Daniel J. Freeman (10 shared papers)Todd Juan (6 shared papers)Rafael G. Amado (3 shared papers)Scott Donald Patterson (2 shared papers)David D. Chang (2 shared papers)Sid Suggs (2 shared papers)Salvatore Siena (2 shared papers)
- Journals
- Molecular Cancer Therapeutics (10 papers)Cancer Research (6 papers)International Journal of Oncology (6 papers)Cancer and Metastasis Reviews (5 papers)International Journal of Cancer (5 papers)
- Partner nations
- United StatesAustraliaItaly
In The Last Decade
Robert Radinsky
120 papers receiving 11.6k citations
Robert Radinsky's Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 6.2k
- Cancer Research 2.2k
- Hepatology 870
- Immunology and Allergy 491
- Biotechnology 678
Countries citing papers authored by Robert Radinsky
This map shows the geographic impact of Robert Radinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Radinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Radinsky more than expected).
Fields of papers citing papers by Robert Radinsky
This network shows the impact of papers produced by Robert Radinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Radinsky. The network helps show where Robert Radinsky may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Radinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 2663 |
| 2 | Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression Hit paper breakdown → | 1995 | 634 |
| 3 | Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. | 1999 | 517 |
| 4 | Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. | 2000 | 449 |
| 5 | 2004 | 404 | |
| 6 | Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. | 2000 | 377 |
| 7 | 1998 | 371 | |
| 8 | Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. | 1994 | 326 |
| 9 | Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. | 2000 | 325 |
| 10 | Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. | 1995 | 286 |
| 11 | 2006 | 254 | |
| 12 | Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. | 1994 | 244 |
| 13 | 2006 | 220 | |
| 14 | Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. | 2000 | 203 |
| 15 | Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. | 2000 | 186 |
| 16 | 2002 | 153 | |
| 17 | 1990 | 148 | |
| 18 | 1994 | 147 | |
| 19 | 2008 | 141 | |
| 20 | 2010 | 137 |
About Robert Radinsky
Robert Radinsky is a scholar working on Oncology, Cancer Research, Hepatology, Molecular Biology and Biotechnology, having authored 122 papers that have together received 12.1k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (30 papers), Angiogenesis and VEGF in Cancer (17 papers), Cancer Cells and Metastasis (16 papers), Cancer-related Molecular Pathways (14 papers), Liver physiology and pathology (14 papers), Cancer Research and Treatments (11 papers), Colorectal Cancer Treatments and Studies (11 papers) and Microtubule and mitosis dynamics (11 papers). The work is most often cited by research in Oncology (6.2k citations), Cancer Research (2.2k citations), Hepatology (870 citations), Immunology and Allergy (491 citations) and Biotechnology (678 citations). Robert Radinsky has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Isaiah J. Fidler, Daniel J. Freeman, Todd Juan, Rafael G. Amado, Scott Donald Patterson, David D. Chang, Sid Suggs, Salvatore Siena, Michael Wolf and Robert S. Sikorski. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, International Journal of Oncology, Cancer and Metastasis Reviews and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.